Top
Rationale and protocol design for the TORG1835/NEXT-SHIP study: a
phase II study of carboplatin, etoposide and nintedanib for unresectable
limited/extensive disease small cell lung cancer with idiopathic pulmonary
fibrosis
Therapeutic Advances in Medical Oncology
Rationale and protocol design for the TORG1835/NEXT-SHIP study: a
phase II study of carboplatin, etoposide and nintedanib for unresectable
limited/extensive disease small cell lung cancer with idiopathic pulmonary
fibrosis
DOI: 10.1177/1758835920923431, Volume: 12, Pages: 0-0
Article Type: research-article,
Article History
received: 2020-3-9
accepted: 2020-4-10
published: 2020-5-18
Altmetric
https://www.researchpad.co/tools/openurl?pubtype=&doi=10.1177/1758835920923431&title=Rationale and protocol design for the TORG1835/NEXT-SHIP study: a
phase II study of carboplatin, etoposide and nintedanib for unresectable
limited/extensive disease small cell lung cancer with idiopathic pulmonary
fibrosis&author=&keyword=[{keywordId=262, uniqueName=etoposide, name=etoposide, contentId=18869}, {keywordId=2706, uniqueName=small-cell-lung-cancer, name=Small cell lung cancer, contentId=18869}, {keywordId=17320, uniqueName=idiopathic-pulmonary-fibrosis, name=idiopathic pulmonary fibrosis, contentId=18869}, {keywordId=21927, uniqueName=carboplatin, name=carboplatin, contentId=18869}, {keywordId=27750, uniqueName=nintedanib, last=true, name=nintedanib, contentId=18869}],[{keywordId=262, uniqueName=etoposide, name=etoposide, contentId=18869}, {keywordId=2706, uniqueName=small-cell-lung-cancer, name=Small cell lung cancer, contentId=18869}, {keywordId=17320, uniqueName=idiopathic-pulmonary-fibrosis, name=idiopathic pulmonary fibrosis, contentId=18869}, {keywordId=21927, uniqueName=carboplatin, name=carboplatin, contentId=18869}, {keywordId=27750, uniqueName=nintedanib, last=true, name=nintedanib, contentId=18869}],[{keywordId=262, uniqueName=etoposide, name=etoposide, contentId=18869}, {keywordId=2706, uniqueName=small-cell-lung-cancer, name=Small cell lung cancer, contentId=18869}, {keywordId=17320, uniqueName=idiopathic-pulmonary-fibrosis, name=idiopathic pulmonary fibrosis, contentId=18869}, {keywordId=21927, uniqueName=carboplatin, name=carboplatin, contentId=18869}, {keywordId=27750, uniqueName=nintedanib, last=true, name=nintedanib, contentId=18869}],[{keywordId=262, uniqueName=etoposide, name=etoposide, contentId=18869}, {keywordId=2706, uniqueName=small-cell-lung-cancer, name=Small cell lung cancer, contentId=18869}, {keywordId=17320, uniqueName=idiopathic-pulmonary-fibrosis, name=idiopathic pulmonary fibrosis, contentId=18869}, {keywordId=21927, uniqueName=carboplatin, name=carboplatin, contentId=18869}, {keywordId=27750, uniqueName=nintedanib, last=true, name=nintedanib, contentId=18869}],[{keywordId=262, uniqueName=etoposide, name=etoposide, contentId=18869}, {keywordId=2706, uniqueName=small-cell-lung-cancer, name=Small cell lung cancer, contentId=18869}, {keywordId=17320, uniqueName=idiopathic-pulmonary-fibrosis, name=idiopathic pulmonary fibrosis, contentId=18869}, {keywordId=21927, uniqueName=carboplatin, name=carboplatin, contentId=18869}, {keywordId=27750, uniqueName=nintedanib, last=true, name=nintedanib, contentId=18869}],&subject=
Get the app for your Mobile or Tablet!
© 2024 Newgen KnowledgeWorks |
Privacy & Cookie Policy | Powered by: Nova